These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 846625

  • 1. Vitamin D-induced hypercalcemia in experimental renal failure.
    Weisbrode SE, Capen CC.
    Nephron; 1977; 18(1):26-34. PubMed ID: 846625
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Model for skeletal resistance to vitamin D in renal failure.
    Weisbrode SE, Capen CC.
    Fed Proc; 1976 Apr; 35(5):1225-31. PubMed ID: 177317
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biologic effects of 1,25-dihydroxycholecalciferol (a highly active vitamin D metabolite) in acutely uremic rats.
    Wong RG, Norman AW, Reddy CR, Coburn JW.
    J Clin Invest; 1972 May; 51(5):1287-91. PubMed ID: 4341503
    [Abstract] [Full Text] [Related]

  • 9. [Drug-induced hypercalcemia].
    Sato K.
    Clin Calcium; 2006 Jan; 16(1):67-72. PubMed ID: 16397353
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hyperammonemic encephalopathy due to vitamin D-induced hypercalcemia in a uremic patient.
    Oymak O, Akpolat T, Arik N, Yasavul U, Turgan C, Cağlar S.
    Nephron; 1994 Jan; 66(3):369. PubMed ID: 8190198
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vitamin D, desferrioxamine and aluminum-induced bone disease in uremic rats.
    Verbeelen D, Smeyers-Verbeke J, van Hooff I, de Roy G.
    Nephron; 1989 Jan; 53(1):54-60. PubMed ID: 2779702
    [Abstract] [Full Text] [Related]

  • 15. Ultrastructural evaluation of the interaction of glucocorticoids and vitamin D on bone cells in thyroparathyroidectomized rats.
    Weisbrode SE, Capen CC.
    Am J Pathol; 1976 Sep; 84(3):457-68. PubMed ID: 961822
    [Abstract] [Full Text] [Related]

  • 16. Effect of vitamin D on growth in experimental uremia.
    Mehls O, Ritz E, Gilli G, Wangdak T, Krempien B.
    Am J Clin Nutr; 1978 Oct; 31(10):1927-31. PubMed ID: 707349
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Atherogenesis in experimental uremia.
    Horsch A, Ritz E, Heuck CC, Hofmann W, Kühne E, Bisson M.
    Atherosclerosis; 1981 Oct; 40(3-4):279-89. PubMed ID: 7332607
    [Abstract] [Full Text] [Related]

  • 19. A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia.
    Sato M, Lu J, Iturria S, Stayrook KR, Burris LL, Zeng QQ, Schmidt A, Barr RJ, Montrose-Rafizadeh C, Bryant HU, Ma YL.
    J Bone Miner Res; 2010 Jun; 25(6):1326-36. PubMed ID: 20200930
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.